Shang Hai Zheng Quan Bao·2025-03-30 19:20Core Viewpoint - The announcement details a correction regarding the capital increase and related transactions between Lijun Pharmaceutical Group Co., Ltd. and its subsidiary Lijun Biopharmaceutical Co., Ltd., clarifying the financial terms and ensuring compliance with regulatory requirements [1][4][5]. Group 1: Correction of Announcement - The company corrected the amount of capital increase from "RMB 100,000.00 million" for "206,449,050 shares" to "RMB 100,000.00 million" for "RMB 206,449,050" in registered capital [1][5]. - The transaction amount is based on fair negotiations to meet Lijun Biopharmaceutical's funding needs, referencing a previous agreement dated November 17, 2023 [1][5][11]. - The operational scope of Lijun Biopharmaceutical was updated to reflect accurate business activities, including medical research and drug production [1][5]. Group 2: Transaction Overview - The company plans to use its own funds of RMB 100,000.00 million to increase the capital of Lijun Biopharmaceutical to support its R&D projects and daily operations [5][11]. - The transaction constitutes a related party transaction due to the shared ownership with the controlling shareholder, Health元 Pharmaceutical Group Co., Ltd., which holds a 45.96% stake [5][7]. - The board of directors approved the transaction with a unanimous vote, ensuring that related directors abstained from voting [6][18]. Group 3: Financial Impact and Strategic Importance - The transaction amount represents 7.21% of the company's latest audited net assets of RMB 1,386,233.42 million [6]. - The capital increase is intended to enhance the financial structure of Lijun Biopharmaceutical, which is crucial for the development of innovative biopharmaceuticals [15]. - The transaction is not expected to adversely affect the company's financial status or operational results [15].